KY SB 211
died on adjournmentAN ACT relating to coverage for prescription drugs.
Kentucky · 2026 Regular Session · upper
Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.
Quick answers
Did KY SB 211 pass?
No. KY SB 211 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-02-19): to Committee on Committees (S)
What is KY SB 211 about?
Create a new section of Subtitle 17A of KRS Chapter 304 to require health plans to include a generic drug or biosimilar on the plan's formulary under specified circumstances; define terms; establish cost-sharing requirements when a generic drug or biosimilar is required to be placed on the health plan's formulary; prohibit a health plan from imposing any prior authorization, step therapy, or other limitation on coverage for a generic drug or biosimilar required to be placed on the health plan's formulary or imposing any restriction on a pharmacist or pharmacy that makes it more difficult for the insured to obtain coverage or access to the generic drug or biosimilar compared to the reference drug or product; amend KRS 304.17C-125, 164.2871, and 18A.225 to require limited health service benefit plans, self-insured group health plans offered by a state postsecondary education institution, and the state employee health plan to comply with the requirements for generic drugs and biosimilars; direct that the Act applies to health plans issued or renewed on or after January 1, 2027; EFFECTIVE, January 1, 2027.
Who sponsors KY SB 211?
C. Richardson is the primary sponsor of KY SB 211.
Description
Create a new section of Subtitle 17A of KRS Chapter 304 to require health plans to include a generic drug or biosimilar on the plan's formulary under specified circumstances; define terms; establish cost-sharing requirements when a generic drug or biosimilar is required to be placed on the health plan's formulary; prohibit a health plan from imposing any prior authorization, step therapy, or other limitation on coverage for a generic drug or biosimilar required to be placed on the health plan's formulary or imposing any restriction on a pharmacist or pharmacy that makes it more difficult for the insured to obtain coverage or access to the generic drug or biosimilar compared to the reference drug or product; amend KRS 304.17C-125, 164.2871, and 18A.225 to require limited health service benefit plans, self-insured group health plans offered by a state postsecondary education institution, and the state employee health plan to comply with the requirements for generic drugs and biosimilars; direct that the Act applies to health plans issued or renewed on or after January 1, 2027; EFFECTIVE, January 1, 2027.
- Introduced
- 2026-02-19
- Latest action
- 2026-02-19 — to Committee on Committees (S)
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- C. Richardsonprimary
Committees
Not provided by source.
Action timeline
Newest first
2026-02-19
to Committee on Committees (S)
referral-committee
2026-02-19
introduced in Senate
introduction
Versions
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:22:24.357326Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=KY&identifier=SB 211. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.